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EGFR oligomerization organizes kinase-active
dimers into competent signalling platforms
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Epidermal growth factor receptor (EGFR) signalling is activated by ligand-induced receptor
dimerization. Notably, ligand binding also induces EGFR oligomerization, but the structures
and functions of the oligomers are poorly understood. Here, we use ﬂuorophore localization
imaging with photobleaching to probe the structure of EGFR oligomers. We ﬁnd that at
physiological epidermal growth factor (EGF) concentrations, EGFR assembles into oligomers,
as indicated by pairwise distances of receptor-bound ﬂuorophore-conjugated EGF ligands.
The pairwise ligand distances correspond well with the predictions of our structural model
of the oligomers constructed from molecular dynamics simulations. The model suggests
that oligomerization is mediated extracellularly by unoccupied ligand-binding sites and that
oligomerization organizes kinase-active dimers in ways optimal for auto-phosphorylation
in trans between neighbouring dimers. We argue that ligand-induced oligomerization is
essential to the regulation of EGFR signalling.
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E
pidermal growth factor receptor (EGFR or HER1/ErbB1)
is a cell-surface receptor tyrosine kinase that plays a
fundamental role in regulation of cellular metabolism,
growth and differentiation1. Dysregulation of EGFR or other
members of the human EGFR (HER) family (HER2/ErbB2/
Neu, HER3/ErbB3 and HER4/ErbB4) is key to the development
of various cancers2. A number of cancer treatment drugs
target HER proteins, and efforts to develop new therapeutic
agents targeting these receptors continue3.
An EGFR protein consists of a ligand-binding extracellular
module and an intracellular module, connected by a single-pass
transmembrane helix. The extracellular module consists of four
domains and the intracellular module of a short juxtamembrane
segment, followed by a tyrosine kinase domain, and a C-terminal
tail, where the ﬁve key phosphorylation sites (Tyr992, Tyr1045,
Tyr1068, Tyr1086 and Tyr1173)4 (Fig. 1a) are located. EGFR
activation depends on ligand-induced receptor dimerization5,6
(Fig. 1a), and the structural arrangement of the ligand-induced
dimers is well characterized. In such an arrangement, the
extracellular domains form a so-called back-to-back dimer7,8
with the two-ligand-binding sites distal from the dimer
interface (Fig. 1a). Dimerization of the extracellular domains,
by conformational coupling across the membrane9,10, promotes
formation of catalytically active asymmetric kinase dimers11
that auto-phosphorylate the C-terminal tails and initiate
downstream signalling.
Pioneering work5,12 showed that EGFR activation is associated
with ligand-induced receptor aggregation, including formation of
dimers or oligomers. Although the mainstream of EGFR research
has largely focused on a dimerization-dependent activation
mechanism, recent analyses suggest that oligomerization also
plays a crucial role in EGFR signalling13. Ligand-induced
EGFR oligomerization was recently characterized14 by using
single-molecule analysis, showing that mutations blocking oligo-
merization reduce auto-phosphorylation of EGFR. Despite the
potential importance of oligomerization in EGFR signalling, key
aspects of EGFR oligomers remain unclear. Here we aim to
elucidate the basic architecture, stoichiometry of ligand binding,
and functional importance of the ligand-binding induced
EGFR oligomers.
Results
The geometry of ligand-bound EGFR oligomers. We used single
ﬂuorophore localization imaging with photobleaching (FLImP) to
investigate the structure of ligand-induced EGFR oligomers15,16,
measuring discrete pairwise separations between ﬂuorophore-
conjugated ligands bound to EGFR complexes (Fig. 1b). Unlike
the single-molecule analysis by Kuriyan and colleagues14,
with ﬂuorophores attached to EGFR intracellularly, we
positioned ﬂuorophores extracellularly and FLImP results reﬂect
the extracellular geometry of ligand-bound EGFR complexes.
FLImP reports lateral separations between identical ﬂuorophores
in the 0–60nm range (cf. ﬂuorescence resonance energy transfer
(FRET), which reports separations between donor/acceptor
ﬂuorophores in the range of 2–8 nm). Given the B11nm lateral
dimension of active EGFR dimers7,8, the dimensions of higher-
order oligomers are expected to fall in the range appropriate
for FLImP experiments. FLImP measurement of the separation
of a pair of ﬂuorophore-conjugated ligands bound to an
EGFR complex produces an empirical posterior probability
distribution of the separation15, taking the form of an
asymmetric Rice distribution17 (Supplementary Fig. 1a–c). The
posterior distribution width (or 69% conﬁdence interval) reﬂects
the precision of each pairwise separation measurement, which
ultimately depends on signal-to-noise (Fig. 1b). The posteriors
with 69% conﬁdence intervals smaller than the required resolution
(typically 4–7 nm) are retained and pooled into a histogram
(hereafter referred to as FLImP distribution), from which one can
derive structural information of EGFR complexes bound to more
than one EGF ligand. From a FLImP distribution one can also
estimate the proportion of measurements consistent with species of
EGFR complexes bound to more than one EGF ligand as an
indicator of the relative population of the species.
We ﬁrst treated Chinese hamster ovary (CHO) cells expressing
wild-type EGFR with a physiological concentration (4 nM) of
EGF conjugated at its N-terminus with CF640R ﬂuorophore
(Biotium) in a 1:1 ratio. At this concentration,B10% of available
EGF-binding sites are occupied by ligands (Supplementary
Fig. 2a). A Bayesian information criterion (see Supplementary
Methods) determines the decomposition of the FLImP
distribution of EGF separations into six Rician peak components
(Fig. 1c). The peak in the range of 0–6.5 nm reﬂects separations
comparable to or below the 4.8 nm resolution of the FLImP
measurements; hence the best-ﬁt position of the peak can be
susceptible to a well understood bias (Supplementary Fig. 1d,e).
For this reason, we quote the conﬁdence interval range but
not the best-ﬁt position. The separations in the other ﬁve peaks
in Fig. 1c fall in the region free from such bias (Supplementary
Fig. 1d,e), and their best-ﬁt peak positions (11.9, 19.9, 29.6,
36.6 and 46.5 nm) reﬂect the underlying pairwise EGF
separations.
Based on crystal structures7,8 and using a dye accessible volume
(AV) algorithm to account for the dimensions of the dye and
linker18 (Supplementary Fig. 2b), we estimate the separation
between ﬂuorophores in a two-ligand back-to-back dimer to fall
in 12.5±0.3 nm. Thus, the peak at 11.9 ( 2.9/þ 2.4) nm
likely represents these dimers (errors are asymmetric because of
the inherent asymmetry of the Rice distribution (Supplementary
Fig. 1a,c)). Peaks in the 19–50 nm range likely reﬂect the
presence of high order EGFR oligomers at physiological
EGF concentrations. Observations suggesting the presence of
EGFR oligomers upon ligand binding were previously reported in
a diverse group of studies (for example, refs 13,14,19,20).
Our ﬁnding here is also consistent with single-particle tracking
data (Supplementary Videos 1 and 2), which showed clusters of
receptors moving together as units in live cells.
In later discussions we show with additional data (Fig. 7a) that
the peak in the range of 0–6.5 nm (Fig. 1c) may represent the
persistent presence of pre-formed inactive EGFR dimers in spite
of exposure to EGF and that these inactive dimers involve the
‘tethered’ conformation21 of the extracellular domains.
A structural model of ligand-bound EGFR oligomers. In
parallel to the FLImP experiments, we attempted to construct a
structural model of EGFR oligomers using long-timescale
molecular dynamics (MD) simulations. Conjecturing that
lattice contacts of existing crystal structures of EGFR and its
homologues might reveal previously unidentiﬁed oligomerization
interfaces, we examined crystal contacts in all published
structures of the extracellular domains of HER family members.
We found a crystallographic dimer of HER3 (PDB 1M6B
(ref. 22)), structurally unrelated to the back-to-back dimer
and featuring an extensive dimer interface (18.8 nm2 in area,
as compared with 14.7 nm2 for the back-to-back dimer
(PDB 1MOX)8). Unlike the back-to-back dimer interface,
which is located on domain II, the crystallographic dimer
interface is located on domains I and III. Since back-to-back
and crystallographic dimer interfaces do not overlap, we
hypothesized that EGFR can oligomerize by making use of
both interfaces simultaneously. As a ﬁrst step in constructing an
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EGFR oligomer model along these lines, we built an EGFR
dimer model using the HER3 crystallographic dimer as a template
(Fig. 2a). In this dimer, two monomers assume the tethered
conformation and the dimerization interface is predominantly
between domain I of one monomer and domain III of the other.
Although dimer interfaces between domains I on one side and
domains III on the other were well maintained in an MD
simulation (6 ms), both monomers departed from the tethered
conformation in a concerted fashion (Supplementary Fig. 5a,b).
This simulation produced a face-to-face extracellular dimer
model, in which each monomer’s conformation is similar to
that in the back-to-back dimer, but the dimer interface is entirely
different. Two back-to-back dimers can be assembled into a
tetramer using the face-to-face interface at domains I and III,
which is located at the opposite side of the back-to-back interface
at domain II (Fig. 2a). Importantly, because the face-to-face
dimer interface largely overlaps with the ligand-binding interface
(Fig. 2b), such a model implies that ligand binding and the
face-to-face dimer interaction are in competition with one
another.
This tetramer model can in principle be extended into
higher-order oligomers by incorporating additional dimers and
repeating the face-to-face interaction. An oligomer of such
structures can bind two EGF ligands at most, as all EGF-binding
sites are engaged in the face-to-face interaction except for the
monomers at the two open ends (Fig. 2c). Separations between
receptor-bound EGF ligands predicted by this model are 18.5 nm
for a tetramer (Fig. 2d), 26 nm for a hexamer, 33.5 nm for an
octamer and 41 nm for a decamer. The oligomer model thus
predicts that peaks in a FLImP distribution of pairwise EGF
separations for a mixture of EGFR oligomers should be
separated by B7.5 nm. Given that the ﬂuorophore diameters
add 1.1±0.5 nm to the 18.5 nm separation between the two
ligands bound to a tetramer (Supplementary Fig. 2c), the
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Figure 1 | FLImP measurement of pairwise EGF separations. (a) Cartoon of an EGFR monomer, a two-ligand active dimer, and an EGFR sequence diagram.
(b) Steps to determine EGF separations using FLImP15: (1) TIRF images are collected from intact cells; (2) spots from individual complexes are tracked to
derive intensity time courses; and (3) a spot image of a complex containing two ﬂuorophore-conjugated EGF ligands (red dots) features two intensity levels
and decays to zero in two bleaching steps; when one ﬂuorophore bleaches, the centroid position shifts. If more than two steps occur, the lowest two are
analysed. (4) A global least-squares seven-parameter-ﬁt is used to identify the best intensity, x-y positions and the full-width at half-maximum of the point
spread function for each ﬂuorophore, from which their separation ðr ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðx1 x2Þ2 ¼ ðy1 y2Þ2
q
Þ is calculated with a precision determined by the
localization error; (5) Example systems of a two-ligand dimer and tetramer, a three-ligand tetramer, and a mixture of a dimer and a tetramer. (6)
The empirical posterior distributions (or FLImP measurement) of pairwise ligand separations obtained for each example system with their 69% conﬁdence
intervals highlighted. The size of the latter depends on the combined localization errors of the two molecules15. FLImP measurements with conﬁdence
intervals smaller than the required resolution are retained in a histogram, generating a so-called FLImP distribution that is ﬁtted by the sum of a discrete
number of Rician peaks (Supplementary Fig. 3a). (c) FLImP distribution (grey) of CF640R ﬂuorophore-conjugated EGF on CHO cells (B105 copies of
wild-type EGFR per cell) treated with 4 nM EGF at 4 C with chemical ﬁxation, compiled from 30 FLImP measurements with conﬁdence intervalso4.8 nm.
The distribution is decomposed into a sum of six Rician peaks. Positions and error estimates are shown in the inset. (Details in Supplementary Methods.)
The peak positions (and error bars) reﬂecting the expected dimers and tetramers are marked above the plot. The optimal number of peak
components (colour lines) and the best-ﬁt (black line) were determined using a Bayesian information criterion and Bayesian parameter estimation
(Supplementary Figs 3b and 4a, and Supplementary Methods).
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separation at 19.9 ( 2.9/þ 3.7) nm suggested by the FLImP
distribution at 4 nM EGF (Fig. 1c) is well within that anticipated
by the tetramer model. Decomposition of the FLImP distribution
also exhibits peaks at 29.6, 36.6 and 46.5 nm, remarkably
consistent with the predictions of the hexamer, the octamer and
the decamer models, especially considering the 4.8 nm resolution
of the FLImP experiment.
We extended the extracellular tetramer model to obtain a
full-length model of the EGFR tetramer (Fig. 2d and
Supplementary Data), based on the previously reported
full-length dimer model9,10 and the naive assumption that the
tetramer is essentially a dimer of the active dimers. When this
model was tested by MD simulations of up to 40 ms, the tetramer
model remained stable, and the two intracellular kinase
dimers formed direct interactions with one another (Fig. 2e).
(For model coordinates see Supplementary Data). Despite
this model, how the intracellular modules interact within
an EGFR oligomer remains obscure. Our mutagenesis studies
suggest that intracellular interactions are crucial to EGFR
oligomerization. The FLImP distribution of the wild-type
receptor at 4 nM EGF (Fig. 1c) exhibits peaks, respectively,
corresponding to underlying dimers (11.9 nm) and tetramers
(19.9 nm). However, at the same EGF concentration, the tetramer
peak is not resolved in the FLImP distribution of DC-EGFR
(the entire intracellular module is truncated) or C’698-EGFR
(the juxtamembrane segment remains) (Fig. 3a,b), suggesting
a decrease of the tetramer population relative to the dimers.
This is quantitatively shown by the reduction in the proportion of
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FLImP measurements consistent with the expected 19.6±0.5 nm
tetramer position (Fig. 3e). On the other hand, the FLImP
distribution of c’973-EGFR, where only the C-terminal tail is
truncated, shows a relative increase of the tetramer population
(Fig. 3c,e).
Oligomerization promotes EGFR auto-phosphorylation. While
it is well established that the active kinase dimer switches on
kinase activity by stabilizing one of the kinase domains in
an enzymatically active conformation11, the mechanism that
ensures substrate access to the activated kinase domain in
EGFR auto-phosphorylation is unclear. In the simulation of the
tetramer model, the two active kinase dimers arrived at an
intriguing arrangement in which a C-terminal phosphorylation
site (Tyr992) from one dimer was positioned adjacent to the
substrate-binding site of the activated kinase of the other (Fig. 2e
and Supplementary Fig. 5d), hinting at the possibility that
EGFR auto-phosphorylation may be realized in the context of
tetramers or higher-order oligomers, occurring in trans between
two neighbouring kinase dimers. A large part of the C-terminal
tail was found to be auto-inhibitory to EGFR phosphorylation23
and deletion of the C-terminal tail (C’973 mutant; Fig. 3c)
promotes tetramer formation. These two ﬁndings together
also suggest a crucial role of oligomerization in EGFR
auto-phosphorylation.
According to our structural model, an oligomer of 2N receptors
can bind to a maximum of two EGF ligands (N:1 stoichiometry)
(Fig. 2c), and an oligomer is a collection of back-to-back dimers
assembled by face-to-face interactions at unoccupied ligand-
binding sites. It follows that at sufﬁciently high EGF concentration,
ligand–receptor interactions may out-compete the face-to-face
interactions and break oligomers into dimers. If indeed EGFR auto-
phosphorylation occurs in the context of oligomers, one should
expect high EGF concentrations to reduce EGFR auto-phosphor-
ylation. To test this somewhat counterintuitive prediction, we
treated CHO cells expressing wild-type EGFR with increasing
concentrations of EGF and measured the level of EGFR auto-
phosphorylation using an antibody (4G10). In these cells, which
do not express any phosphorylatable proteins of similar size to
EGFR24, 4G10 speciﬁcally recognizes all EGFR phosphotyrosines.
The data in Fig. 4a show a biphasic EGF dependence of
EGFR auto-phosphorylation, peaking at B30nM EGF and, as
anticipated, returning to the basal level at 1–5mM EGF.
To investigate whether high EGF concentrations break
oligomers into ligand-bound dimers, we performed FLImP
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Figure 4 | Dependence of EGFR phosphorylation and oligomerization-related structural parameters on ligand concentration. (a) Western blot
measurement of wild type total EGFR auto-phosphorylation in CHO cells exposed to increasing concentrations of EGF. The monoclonal pan-phosphotyrosine
antibody 4G10 was used in the measurements. Data points and standard deviations are derived from the average of three independent measurements
(examples western blot images shown in Supplementary Fig. 6c). (b) Similar to Fig. 3e, estimate of the relative population of EGFR dimers. The estimates are
based on the wild-type FLImP distributions at varying EGF concentrations (Fig. 3e and Supplementary Fig. 7). Errors are calculated as in Fig. 3. (c) Western blot
measurements of phosphorylation of Tyr1173 and Tyr992 in CHO cells exposed to increasing EGF concentrations. Data points and error bars (s.d.) are
derived from the average of four independent measurements (examples shown in Supplementary Fig. 6a,b). For the Tyr992 data, P values were calculated
using Student’s t-test to determine whether measured phosphorylation at high EGF concentrations was signiﬁcantly different from the maximum
phosphorylation value measured at 100nM EGF. P values are: 50nM EGF, P¼0.058; 200nM EGF, P¼0.173; 500nM EGF, P¼0.027; 1,000nM EGF,
P¼0.014; 2,000nM EGF, P¼0.011; 5,000nM EGF, P¼0.009. (d) The DOCA between EGFR-bound EGF molecules and the membrane, derived from FRET
measurements shown in Supplementary Fig. 8. DOCAs were obtained from 1,000 bootstrap data sets (that is, data sets resampled with replacement).
The error bars are the standard deviations of the bootstrap means. Simulations of the tetramer (Fig. 2d and Supplementary Fig. 5c) and dimer9
(bottom left inset) predict a DOCA of B5nm for oligomers and B7.5 nm for dimers.
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experiments at increasing concentrations of EGF on CHO cells
expressing wild-type EGFR (Supplementary Fig. 7). If EGF out-
competes face-to-face interactions, at higher EGF concentration
one would expect an increase in pairwise EGF separations
consistent with back-to-back dimers. This is indeed what we
found (Fig. 4b). At EGF concentrations beyond 100 nM, at
which EGFR auto-phosphorylation begins to return to the basal
level, there is an overall increase in separations consistent
with dimers (12.5±0.3 nm). This ﬁnding supports the notion
that the decline in EGFR auto-phosphorylation is associated with
disruption of oligomerization.
To further characterize EGFR auto-phosphorylation, we
examined phosphorylation of Tyr1173 and Tyr992. Tyr1173 is
the ﬁrst of the ﬁve C-terminal tyrosine phosphorylation sites to be
phosphorylated after EGF binding25. Of these sites, Tyr1173 is
also closest to the C-terminus (most distal to the kinase domain
in sequence) and is preceded by an unstructured loop of over 200
residues (Fig. 1a). We reasoned that the length and ﬂexibility of
the loop may allow Tyr1173 access to an activated kinase domain
in cis within an EGFR dimer and if so, Tyr1173 phosphorylation
may be unique in its independence from EGFR oligomerization.
Consistent with this hypothesis, using a pTyr1173-speciﬁc
antibody we showed that, in contrast to the overall EGFR
auto-phosphorylation (Fig. 4a), Tyr1173 phosphorylation
plateaus at B500 nM EGF and remains high up to 5mM EGF
(Fig. 4c).
Tyr992, on the other hand, is the tyrosine phosphorylation site
most proximal to the kinase domain in sequence, and
topologically unique among the other EGFR C-terminal
tyrosines26. We reasoned that the phosphorylation of Tyr992,
unlike Try1173, may have to be realized in trans between
neighbouring dimers within an oligomer (Fig. 2e). Indeed the
phosphorylation of Tyr992 shows a decrease at EGF
concentrations beyond 100–200 nM (Fig. 4c), where the fraction
of dimers is higher (Fig. 4b). This decrease is statistically
signiﬁcant, as shown by P values given in the ﬁg. 4 caption.
Since pTyr992 and pTyr1173 recruit different effectors27
and elicit different downstream signals, these signals may
respond differently to a shift in EGF concentration.
Another simulation prediction is that, on average, an
oligomer-bound ligand is positioned closer to the membrane
than a dimer-bound ligand. In our molecular model of the
oligomer, the extracellular modules of two EGFR dimers engaging
in face-to-face interactions with one another must tilt in
opposite directions. In comparison, the extracellular module of
an active EGFR dimer ﬂuctuates around an upright orientation.
In our previous simulation (4.4ms) of the back-to-back dimer9,
EGF ligands are at an average distance of 7.7±2.7 nm from the
membrane; in another simulation carried out in this study
(6.4ms), the distance was 7.5±2.5 nm. By contrast, the
average distance of the N-termini of tetramer-bound ligands
to the membrane was smaller, 6.4±0.9 nm in one simulation
of our tetramer model and 5.0±0.95 nm in another
(Supplementary Fig. 5c).
We employed FRET to measure the distance of the closest
approach (DOCA)28 between donor Alexa 488-conjugated EGF
ligands and acceptor DiD probes embedded in the membrane
(Supplementary Fig. 8a–e). If high EGF concentrations indeed
result in breaking EGFR oligomers into dimers, we expect
EGF-membrane distance to increase at high EGF concentrations.
As shown by DOCA, the average EGF-membrane distance rises
from 4.8±0.9 nm at 4 nM EGF to 8±0.8 nm at 400 nM EGF and
7.5±0.8 at 1 mM EGF (Fig. 4d). Importantly, the increase of EGF
distance to the membrane is in line with the relative increase in
FLImP readings of EGF separations consistent with dimers
(Fig. 4b) at the expense of readings consistent with tetramers.
The R647C/V650C mutant, which is palmitoylated in the
juxtamembrane segment at the two cysteines, is another example
where impaired auto-phosphorylation29 coincides with an increase
in the FLImP readings of EGF separations consistent with dimers
(Fig. 5a–c), and in the average ligand–membrane distance
(7.1±0.6 nm) (Fig. 5d). The FLImP distribution of R647C/
V650C at 4 nM EGF, reminiscent of the wild-type distribution at
1mM EGF (Supplementary Fig. 7d), suggests that oligomerization
is hindered by the double mutation. We further showed that,
similar to the effect of high EGF concentration on the wild-type,
R647C/V650C palmitoylation impairs overall EGFR auto-
phosphorylation but not phosphorylation of Tyr1173 (Fig. 5f
and Supplementary Fig. 6d for western blot images). Simulation
studies suggest that the effect of R647C/V650C may arise from the
extension of the hydrophobic length of the transmembrane helices
due to palmitoylation (Fig. 6f).
Our oligomer model correctly anticipates that high EGF
concentrations would lead to the breaking of EGFR oligomers
into two-ligand dimers (Fig. 3d and Supplementary Fig. 7b). The
model, however, does not explain the re-emergence of the peaks of
large EGF separations at higher than physiological EGF concen-
trations (400nM and 1mM; Supplementary Fig. 7c,d). Formation
of oligomers at non-physiological concentrations has previously
been reported14. We cannot provide a deﬁnitive explanation for
this phenomenon, but speculate that other forms of EGFR
oligomers with different EGF stoichiometry may dominate at
EGF concentrations far beyond physiological. This is supported by
two ﬁndings. First, the oligomers formed at EGF concentrations
4100 nM are not only smaller than those formed ato30nM EGF
(Fig. 6a), but also display a different geometry (Fig. 6b and
Supplementary Fig. 7b–d). Secondly, unlike EGFR oligomers at
low EGF concentrations, those at high concentrations are not
conﬁned within plasma membrane compartments. EGFR is known
to interact with phosphatidylinositol 4,5-bisphosphate lipids (PIP2)
(ref. 20). The similarity of mean square displacement (MSD) plots
from tracking EGFR and tracking PIP2 on the cell surface (Fig. 6c)
suggests that EGFR oligomers formed at 4 nM EGF are conﬁned
in (PIP2)-enriched plasma membrane regions. In contrast,
EGFR oligomers formed at 400 nM EGF are not conﬁned to
PIP2-enriched regions. These results suggest that EGFR oligomers
at low- and high EGF concentrations occupy different plasma
membrane regions, raising the possibility that plasma membrane
environment may inﬂuence EGFR oligomer geometry.
Membrane bending and EGFR oligomerization. Our
simulations of the tetramer model showed an intriguing local
thinning of the membrane and spontaneous formation of negative
membrane curvature centred on the transmembrane helices
(Fig. 6d,f) organized into two N-terminal helix dimers (dimer
interfaces near the N-terminus of the helices). The transmembrane
dimers organized by oligomers may insert in the membrane as
hydrophobic wedges (Fig. 6d) are known to promote local bending
of the membrane30. Extracellular and intracellular modules of the
oligomers also form intimate contacts with the membrane surfaces,
potentially exerting a sculpting effect on the membrane. It is
conceivable that clustering of EGFR oligomers may induce
membrane bending, and conversely, interference with membrane
bending may affect EGFR oligomerization.
Previous work showed a complex interplay between membrane
curvature and cholesterol distribution in lipid bilayers31. Of
particular interest, the presence of cholesterol is found to help
induce negative membrane curvature32. To test coupling
between membrane curvature and EGFR oligomerization, we
used FLImP to measure EGF pairwise separations at 4 nM EGF in
the presence of 10mM methyl-b-cyclodextrin (MbCD), which
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removes cholesterol from the membrane19,33. Addition of MbCD
signiﬁcantly altered the FLImP distribution, suggesting a changed
oligomerization pattern. Intriguingly, the FLImP distribution at
4 nM EGF with MbCD (Fig. 6e) is remarkably similar to the
distribution at 400 nM EGF without MbCD (Fig. 6b). A
quantitative analysis shows that oligomers formed at 4 nM EGF
with MbCD are smaller than those at 4 and 30 nM EGF in the
absence of MbCD (Fig. 6a). Consistent with this, the MSD plot
derived from tracking EGFR oligomers formed at 4 nM EGF in
cells pre-treated with MbCD shows a reduction in conﬁnement of
receptor complexes in PIP2-enriched regions of the membrane of
comparable magnitude to that found for 400 nM EGFR in the
absence of MbCD (Fig. 6c). This again suggests that plasma
membrane environments may inﬂuence the geometry of EGFR
complexes.
The MbCD results are consistent with cooperativity between
membrane bending and EGFR oligomerization, which may help
clustering of active EGFR oligomers in clathrin-coated pits34
and internalization of EGFR, a key mechanism for negative
feedback in EGFR signalling35. Such a scenario would provide an
explanation for the connection of EGFR internalization and
enhanced EGFR oligomerization. Further research is required to
fully establish this connection and to clarify the molecular
mechanism behind it.
Inactive EGFR dimers of the tethered conformation. As noted
earlier, the FLImP distribution at 4 nM EGF exhibits a short peak
in the range of separations of o6.5 nm (Figs 1c and 7a) that
cannot be explained by our model (Fig. 2d). Similar short
EGF separations were previously observed using FRET (for
example, refs 13,36). Echoing this observation, the FLImP
distribution of CF640R ﬂuorophore-conjugated anti-EGFR
Afﬁbody antagonist37 showed a peak in the range of
separations of o8 nm (Fig. 7b). As the Afﬁbody inhibits EGFR
activity and competes with EGF for the same binding site37,38,
this Afﬁbody peak likely reﬂects a set of complex structures of
inactive receptors. Quantum-dot-based optical tracking showed
that in the absence of EGF, EGFRs form inactive or ‘pre-formed’
dimers of ﬁnite lifetime that are primed for ligand binding39.
Modelling based on MD proposed an active-like extracellular
structure of the inactive dimer9, while other analysis40 argues that
the extracellular domains of the inactive dimers are structurally
diverse and the constituent monomers may assume the tethered
conformation. The corresponding peak in the FLImP distribution
of EGF ligands suggests that such inactive EGFR complexes
persist despite the presence of EGF. When 200 nM 9G8
anti-EGFR nanobody is added to the Afﬁbody treatment,
the population of short Afﬁbody separations detected by
FLImP increases (Fig. 7c,d). Because 9G8 binding to EGFR is
non-competitive with Afﬁbody binding (Supplementary Fig. 9)
and is selective to the tethered conformation (Fig. 1a)41, the short
Afﬁbody separations likely reﬂect inactive EGFR dimers with
tethered conformation. The Afﬁbody FLImP distributions exhibit
a second prominent peak at 12.0±1.6 nm (Supplementary Fig. 4b
and Fig. 7b), indicative of another form of inactive dimers.
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Figure 5 | Pairwise EGF separations and phosphorylation of R647C/V650C. (a) FLImP distribution (grey) of pairwise EGF separations on CHO cells
expressing the R647C/V650C-EGFR mutant at a level ofB105 copies per cell. The separations whose conﬁdence intervals overlap with the 12.5±0.3 nm
(green) or 19.6±0.5 nm (yellow) expected dimer and tetramer interval are shown. The expected intervals are indicated by the vertical blue lines. The
distribution includes data from 40 FLImP measurements with conﬁdence intervalso6 nm. (b) Peak decomposition (colour lines) and best-ﬁt (continuous
black line) of the FLImP distribution. The optimal number of underlying peak components (colour lines) and the best-ﬁt (black line) were determined using
a Bayesian information criterion. The best-ﬁt positions of the peaks and error bars are shown in the inset. (c) Similar to Fig. 3e, an estimate of the relative
populations of dimers and tetramers. (d) Comparison of EGFR R647C/V650C and the wild-type receptor in terms of DOCA distances between
receptor-bound EGF molecules and the membrane at 4 nM EGF derived from FRET measurements shown in Supplementary Fig. 8f. (e) Overall and
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The diminishment of this peak by 9G8 (Fig. 7c) suggests that the
alternative inactive dimer is not tethered.
Control experiments against FLImP artefacts. Receptors must
be completely immobilized on cells at the nanometre scale to
achieve resolutions below 10 nm. Our FLImP experiments
therefore use chemical ﬁxation (3% paraformaldehyde þ 0.5%
glutaraldehyde), which is widely used and compatible with the
total internal reﬂection ﬂuorescence (TIRF) illumination method
used for FLImP (Fig. 1b). Chemical ﬁxation could in principle
introduce crosslinking artefacts. To investigate this possibility, in
a previous report16 we showed that FLImP reproduced the
breaking of higher-order EGFR oligomers into dimers upon
receptor downregulation by phorbol myristate acetate (PMA)
activation of protein kinase C (PKC), a signalling effector
downstream to EGFR. Moreover, we showed that PKC
inhibitor bisindolylmaleimide-I (BM-I) cancels out the effect of
PMA treatment16. As PMA does not abolish the ability
of EGFR to interact at the plasma membrane with one
another (Supplementary Fig. 10a–e), the results of our
previous PMA/BM-I control experiments are inconsistent with
an overriding chemical crosslinking artefact in our FLImP
measurements.
In a separate report42, we showed that FLImP distributions
change as expected upon cholesterol removal from the
membrane. Here in this study we showed clustering of
receptors moving together in units larger than dimers on live
cells (Supplementary Videos 1 and 2). Moreover, we showed that
high EGF concentrations (Figs 4 and 6) and EGFR mutations
(Figs 3 and 5) can disrupt oligomerization. The number and
brightness of receptor particles detected on the cell surface
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Figure 6 | Membrane bending and EGFR oligomerization. (a) Percentage of separations whose 69% conﬁdence intervals overlap with the dimer/tetramer
range (ro20.1 nm) or do not (r4 20.1 nm), estimated by the ratio of the integral area of interest (purple or salmon in FLImP distributions, Supplementary
Fig. 7) to the integral area of the distribution. (b) FLImP distribution (grey) of pairwise separations of ﬂuorophore-conjugated EGF on CHO cells expressing
B105 copies of wild-type EGFR treated with 400 nM EGF (46 measurements). The distribution is ﬁtted (black line) with a sum of ﬁve Rician peaks (colour
lines). Best-ﬁt positions and error bars shown in the inset. (c) (green) MSD plot from single-particle tracks of wild-type EGFR complexes on live CHO cells
at 37 C labelled with Alexa 488-conjugated EGF; (dark blue) MSD plot from single-particle tracks of PIP2 labelled with a PLCd1-Pleckstrin homology (PH)
domain (PH-eGFP) fusion construct which speciﬁcally binds PiP2 (ref. 75), transfected on CHO cells expressing wild-type EGFR. MSD plots include data
from B4103 tracks and three biological repeats. Bootstrap-estimated errors (vertical line) are shown. Linear MSD plots suggest Brownian motion;
concave-down MSD plots suggest conﬁnement at the plasma membrane76. (d) The negative curvature of the membrane local to an EGFR tetramer in
simulation. The cartoon illustrates the membrane-bending effect of the N-terminal dimers of EGFR transmembrane helices as a hydrophobic wedge.
(e) FLImP distribution (grey) of pairwise separations of ﬂuorophore-conjugated EGF on the surface of CHO cells expressingB105 copies of wild-type EGFR
pre-treated with 10mMMbCD, exposed to 4 nM EGF (33 measurements). Best-ﬁt positions and error bars are shown in the inset. (f) Membrane thickness
(Y-axis) as a function of distance to the transmembrane helices (X-axis) in simulations of the wild-type active dimer and tetramer, and the palmitoylated
R647C/V650C tetramer. The membrane thickness is indicated by the average separation between the two sheets of phosphorus atoms of the two lipid
layers. The wild-type tetramer (red line) exhibited a more pronounced membrane-thinning effect. The data are plotted as averages and standard error of
the mean over frames of the simulations.
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remain constant before and after treatment with crosslinking
reagent (Supplementary Fig. 11a) and, as shown by
photobleaching image correlation spectroscopy43, sizes of EGFR
clusters remain unchanged after ﬁxation (Supplementary
Fig. 11b). These ﬁndings, combined with the effects of PKC
inhibitors on EGFR oligomerization, strongly argue against the
possibility of signiﬁcant crosslinking artefacts in the FLImP
experiments.
We employed low-temperature incubation (B4 C) to block
EGFR-mediated coated pits from entry into the cell44, a process
that begins seconds after the ligand stimulus45 at physiological
temperature. Published data suggest that EGF binding to EGFR
proceeds as normal at 0 C (ref. 46), and that low temperature
does not change EGFR localization33 nor signiﬁcantly affect
EGFR phosphorylation and signalling20,45. Exposing cells to low
temperatures can in principle depolymerize the cytoskeleton47
and alter the size of plasma membrane domains48, both of which
may disrupt EGFR interactions with one another and introduce
artefacts. We found that depolymerizing the F-actin and
microtubule networks by treating cells with Latrunculin A49 or
Nocodazol50, or altering the size of plasma membrane domains
by treating cells with Nystatin or MbCD (ref. 33), have signiﬁcant
effects on the size of the plasma membrane compartments in
which EGFR diffuses (Supplementary Fig. 10a), the rate of
EGF-induced oligomerisation (Supplementary Fig. 10b), and the
half-life of EGFR complexes (Supplementary Fig. 10c). In
contrast, the size of the membrane compartments, the rate
of EGF-induced oligomerization, or the half-life of EGFR
complexes after low-temperature incubation are statistically
indistinguishable from those after incubation at 37 C
(Supplementary Fig. 10a–e), suggesting that low-temperature
incubation used in our experiments does not introduce signiﬁcant
artefacts. The only noticeable effect of low temperature is a
reduction in the diffusion rate of EGFR (Supplementary Fig. 10d),
as reported previously44.
We then used Afﬁbody FLImP experiments as another layer
of control against potential artefacts of low-temperature
incubation. Given that Afﬁbody does not activate the receptor42
(Supplementary Fig. 9), and therefore does not induce receptor
mediated endocytosis, we compared the FLImP distribution
obtained after low-temperature incubation to that with
Afﬁbody probe at room temperature (B21 C), at which actin
polymerization kinetics in vitro proceed as normal47.
Reassuringly, the FLImP distributions were quantitatively
indistinguishable (Supplementary Fig. 12), again suggesting that
the low temperature does not introduce signiﬁcant artefacts.
We next enquired whether low-temperature incubation was
sufﬁcient to alter the cytoskeleton. To test this, we used
ﬂuorescence microscopy under epi-illumination and TIRF
illumination to compare the inner and cortical actin cytoskeleton
in cells incubated at 4oC for 1 h with those of cells not subjected
to this treatment. As shown in Supplementary Fig. 13, the
distribution and abundance of actin ﬁlaments is indistinguishable.
While in principle it remains possible that certain artefacts may
have escaped our scrutiny and affected our results, we believe that
the substantial body of controls (Supplementary Figs 10–13) in
this work and previous ﬁndings by us42,51 and others (for example,
refs 20,33,45,46) rule out any signiﬁcant artefacts associated with
chemical crosslinking or low incubation temperature adopted in
the FLImP protocol.
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Discussion
In summary, a body of data acquired from a multi-technique
study (involving high-resolution FLImP, FRET, long-timescale
MD simulations, single-particle tracking and biochemical assays)
suggests that efﬁcient EGFR auto-phosphorylation requires the
formation of at least EGFR tetramers. While ligand-induced
dimerization is fundamental in ensuring the activation of
EGFR kinases, oligomerization is likely also essential in ensuring
efﬁcient substrate access to the activated kinases. We propose a
structural model of EGFR oligomers by which an oligomer binds
two EGF ligands, involving a previously not discussed interaction
of two neighbouring EGFR molecules mimicking their interaction
with EGF. Results on intracellular mutants of EGFR suggest
that interactions of the intracellular kinase domains are crucial to
oligomerization, but further high-resolution investigations are
needed for a clear understanding of these interactions.
It is tempting to speculate that the structural basis of EGFR
oligomerization we propose may also be applicable to other HER
family members. Although the formation of HER2/HER3 dimers
appears to be sufﬁcient for HER3 phosphorylation, it was
suggested that phosphorylation of HER2 may require higher-order
HER2/HER3 complexes52. Recently, it was also suggested that
higher-order oligomerization may explain why phosphorylation of
the C-terminal tail of HER receptors is always asymmetric,
independent of the sequence of the tail23. Indeed, the tail of the
activator is always more phosphorylated, and this may not be
accounted for by contacts within an asymmetric dimer, while
higher-order oligomerization can sterically determine the access of
the tail to activated kinases in other dimers23. It was further
suggested that HER3 oligomerization involves two distinct
interfaces: one where interactions are independent of ligand
binding and another where interactions are disrupted by it53. This
is intriguingly reminiscent of the back-to-back and face-to-face
interactions involved in our model of EGFR oligomers. Moreover,
our results imply that ligand binding at higher concentrations is
energetically less favourable because it disrupts face-to-face
interactions in oligomers. This may be an important factor
contributing to the negative cooperativity of EGFR ligand
binding54.
This study suggests biphasic EGFR signalling based on an
intricate balance of EGFR dimers and oligomers modulated by
ligand concentration and binding afﬁnity. The model proposes that
a relatively low ligand concentration is sufﬁcient to elicit a high
degree of EGFR auto-phosphorylation, explaining the ‘super-
stoichiometric’ signalling behaviour displayed by EGFR at low EGF
concentrations. (The number of phosphorylated EGFR molecules
is approximately threefold larger than that afforded by the number
of bound EGF molecules55 and the Grb2:EGFR recruitment
stoichiometry can be as high as 3.5:1 (ref. 56).) In contrast, high
EGF concentration hinders EGFR oligomerization and suppresses
Tyr992 phosphorylation (but not Tyr1173). Instead of a
simple positive correlation between signalling and ligand
concentration, there could be at least two distinct responses to
stimulus and differential biological consequences: one associated
with Tyr1173 phosphorylation, and another associated with
Tyr992 phosphorylation, as suggested by proteomic studies27
and by results that associate oligomerization closely with
Tyr992 phosphorylation and PI3K activation but not with distal
C-terminal phosphorylation of ERK14. Indeed, it was also reported
that, while low EGF concentrations can activate most canonical
pathways (for example, Erk, Akt, Shc1, CrkL, Cbl and Gab1)57,
high EGF concentrations trigger pathways of ubiquitination
and non-clathrin endocytosis58, tyrosine dephosphorylation of
p130Cas, actin cytoskeleton rearrangement59, inactivation of
Src60, activation of phospholipase C-gamma 1 (PLCg1)57 and
apoptosis61. Differences in binding afﬁnities among EGFR
ligands62 may also modulate the dimer-oligomer balance, giving
rise to differential biological consequences downstream.
Methods
Cell culture. All reagents unless otherwise stated were from Invitrogen, UK. CHO
cells expressing wild-type EGFR or an EGFR mutant (R647C/V650C-EGFR,
DC-EGFR, C’698-EGFR and C’973-EGFR) under an inducible Tet-ON promoter
were a gift from Prof Linda Pike (Washington University). Cells were grown in 5%
CO2 in air at 37 C in phenol-red-free DMEM supplemented with 10% (v/v) fetal
bovine serum, 2mM glutamine, 1% penicillin-streptomycin, 100mgml 1 hygro-
mycin and 100mgml 1 geneticin. CHO cells with stably transfected EGFR-eGFP
were a gift from Prof. Donna Arndt-Jovin (Max Planck Institute for Biophysical
Chemistry). All cells used were regularly tested for mycoplasma contamination.
Fluorophore localization imaging with photobleaching (FLImP). The method
was ﬁrst described in ref. 15. Brieﬂy 1 105 cells were seeded on 1% BSA-coated
Piranha cleaned 35mm no. 1.5 (high tolerance) glass-bottomed dishes
(MatTek Corporation, USA) in 2ml of media plus 50 ngml 1 of doxycycline
hyclate (Sigma), resulting in expression ofB105 receptors per cell3. After 48 h the
medium was changed to 0.1% serum plus 50 ngml 1 doxycycline for 2 h. CHO
cells were rinsed and cooled to 4 C for 10min and then labelled with 4 nM
EGF-CF640R or Afﬁbody-CF640R for 1 h at 4 C. The N-terminus of EGF was
labelled at a 1:1 ratio by Cambridge Research Biochemicals (Cleveland, UK).
The EGFR Afﬁbody was labelled at a 1:1 ratio at its single cysteine residue. For the
EGF concentration curve EGF-CF640R was mixed with unlabelled EGF to the
required concentration. Cells were rinsed and ﬁxed with 3% paraformaldehyde plus
0.5% glutaraldehyde for 15min at 4 C, then 15 min at room temperature. If
required, cells were pre-treated for 1 h on ice at 4 C with 200 nM 9G8 nanobody4
dissolved in PBS or for 30min at 37 C in 10mM MbCD. We used an Axiovert
200M microscope with TIRF illuminator (Zeiss, UK), with a  100 oil-immersion
objective (a-Plan-Fluar, NA¼ 1.45; Zeiss, UK) and an EMCCD (iXon X3; Andor,
UK). The microscope is also equipped with a wrap-around incubator (Pecon XL
S1). Samples were illuminated using a VortranStradus 638 nm diode laser
(Laser Technology, Inc., USA) or a ﬁbre-coupled laser combiner (Andor) with a
100mW 640 nm diode laser (Cube, Coherent). Images were collected every 0.28 s.
For each experiment, B120,000 single-particle image spots were obtained from at
least 750 cells and at least three biological repeats. Empirical posterior FLImP
distributions were then obtained based on discrete EGF or Afﬁbody separation
measurements that had conﬁdence intervals of less than 6–7 nm. A more detailed
description of the FLImP method can be found in ref. 15, and the theoretical basis
of the method is described in Supplementary Methods.
Characterisation of EGF and afﬁbody binding. CHO cells expressing wild-type
EGFR were seeded in 2ml of media with 250 ngml 1 of doxycycline (B4 105
receptors per cell) and labelled with the required concentration of either EGF- or
Afﬁbody-Alexa 488 for 1 h at 4 C on ice. Cells were rinsed and ﬁxed as described
above. Twenty confocal images of equatorial regions of the cells were collected per
concentration from three replicates. We used a Leica TCS SP8 microscope with a
(NA¼ 1.4; Leica) and a Leica HyD hybrid detector. Samples were illuminated with
488-nm light taken from an NKT Extreme supercontinuum light source. The pixel
size of the confocal images was 75 75 nm. The ﬂuorescence intensity values of
pixels contributing to cell membranes were extracted to create a frequency
distribution of membrane pixel intensities for each concentration of EGF- and
Afﬁbody-Alexa 488. The median intensity value was plotted as a function of
concentration, with error bars representing the upper and lower quartiles of the
distribution. To test the effect of binding the 9G8 nanobody to EGFR on the
subsequent binding of EGF- and Afﬁbody-Alexa 488, CHO cells were pre-treated
with 200 nM 9G8. Frequency distributions of membrane pixel intensities were
obtained as above and compared with the distributions derived from 200 nM
EGF- or Afﬁbody-Alexa 488 without 9G8.
Modelling distances between dye pairs. To determine the expected distances
between dye pairs in EGFR dimers and tetramers, taking into account the length of
the linker and dimensions of the dye molecule, we used a geometric AV algorithm,
originally developed for characterizing FRET experiments18. Although the
structure of CF640R is proprietary, the manufacturer provided us with information
on the linker and dye structure that has enabled us to determine its dimensions
(Biotium, personal communication). The software for modelling is available on the
authors’ website (http://www.mpc.hhu.de/en/software/fps.html). A PDB ﬁle of the
structure of either dimer (1ivo.pdb7) or tetramer (model described in the main text,
Fig. 2d) was loaded into the ‘AV simulation’ software. For each of the ﬂuorescent
labels, the attachment atom was speciﬁed together with dye and linker dimensions,
using a three radius model for the dye. The software outputs both a mean dye
position and an AV cloud describing the area accessible to the ﬂuorophore.
Average distances between dyes were calculated using the ‘FPSgui’ software, giving
dye to dye distances of 12.5±0.3 nm for the dimer, and 19.6±0.5 nm for the
tetramer. The models are shown in Supplementary Fig. 2b,c.
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FRET distance of closest approach (DOCA). Uncoated 35mm no. 1.5
glass-bottomed dishes were seeded with 1 105 CHO cells expressing wild-type
EGFR in 2ml of media with 250 ngml 1 of doxycycline (B4 105 receptors
per cell). After 2 days, the medium was changed to 0.1% serum with the same
concentration of doxycycline for 2 h. Samples were labelled with 5 mM C18 DiD for
10min at 37 C, followed by the required mixture of EGF-Alexa 488 and unlabelled
EGF at 4 C on ice for 1 h. Samples were ﬁxed with 3% paraformaldehyde as
described above.
Images were collected at room temperature using a Nikon Eclipse C1 confocal
microscope with time-correlated single-photon counting electronics (SPC830,
Becker-Hickl GmbH) using a supercontinuum light source (Fianium SC450-4;
40MHz repetition rate). For each ﬁeld of view, a TCSPC image of Alexa 488 was
obtained using 488 nm excitation and ﬂuorescence detection between 505 and
530 nm using a fast photomultiplier tube (PMC-100; Becker-Hickl GmbH).
Corresponding confocal intensity images of Vybrant DiD (DOCA) were collected
with 640 nm excitation and detection between 670 and 720 nm.
Fluorescent intensity decays were best-ﬁtted to a single exponential decay
model, where acceptor was absent and to a bi-exponential model when both donor
and acceptor were present using SPCImage FLIM analysis software (Becker-Hickl
GmbH). Donor lifetimes for FRET efﬁciency calculations were obtained by taking
the mean of the distribution of the ﬂuorescence lifetimes of pixels. The occurrence
of FRET results in a decrease in the ﬂuorescence lifetime of the donor tD in cells
loaded with acceptor tDA. The FRET efﬁciency (EFRET) was calculated from
ﬂuorescence lifetime data using the following formula:
EFRET ¼ 1 tDtDA
For each cell in the FLIM images, regions of interest were drawn to isolate the
membrane and the mean lifetime from these pixels was used to calculate a mean
FRET efﬁciency. The same region of interest was then applied to the corresponding
image of of Vybrant DiD labelling to determine the corresponding mean acceptor
intensity for that cell. The mean acceptor intensity was converted to a density
with units of acceptors per R02 using a calibration factor previously determined from
samples with a known DOCA28. A model obtained from Monte Carlo simulations of
a single donor at different distances above a plane of acceptors was ﬁtted to each data
set to estimate the ensemble averaged DOCA for that experiment.
Western blots. CHO cells were seeded in 10 cm plates at the density of 6 105
cells per dish with 250 ngml 1 doxycycline hyclate (Sigma). Forty-eight hours
later, cells were washed 2 with ice-cold PBS, then chilled for 10min on ice and
incubated on ice with ice-cold EGF for 1 h at 4 C using 3ml solution per dish, then
wash 2 with ice-cold PBS. Cells were scraped into PBS þ inhibitors (phos-
phatases and proteases) and spun down. Cells were lysed in 10 volume of
M-PER þ 100mM NaF þ 1mM Na3VO4 þ 1% protease inhibitors þ 150mM
NaCl þ 1mM EDTA at pH 8 and incubated for 10min at room temperature.
Cells were cleared by centrifugation and total protein measured. Sample buffer was
added to 1 ﬁnal concentration. Samples were run in parallel on 1.0-mm thick
(or 1.5-mm thick for EGF response curve), 3–8% Tris-Acetate NuPAGE gels
(Invitrogen) with HiMark Prestained HMW and Novex Sharp Prestained protein
standards (Invitrogen) using an XCell apparatus (Invitrogen). Proteins were blotted
using an iBlot system (Invitrogen) on polyvinylidene diﬂuoride membranes,
blocked for 1 h at 4 C with 5% BSA in TBSþ 0.1% Tween and probed overnight
with mouse anti-phosphotyrosine 4G10, 1:1,000 (05-321), rabbit anti-EGFR
pY1173 1:1,000 (04-341) (both Upstate (Millipore)) or mouse anti-EGFR pY992
antibody [EM-12] (ab81440) (Abcam). Gels were probed with secondary anti-
mouse or anti-rabbit horseradish peroxidase antibody (Jackson ImmunoResearch)
and incubated with Supersignal West Pico Chemiluminescent Substrate solution
(Pierce) for 5min, then imaged with a BioRad ChemiDoc MP system imager. Each
blot was stripped with 25ml stripping buffer (2% SDS, 0.75% b-mercaptoethanol,
62.5mM Tris HCl pH 6.7) for 50min at 60 C, and re-probed with an anti-EGFR
cocktail composed of anti-EGFR D38B1, 1:2,000 (#4264) (Cell Signalling
Technologies), anti-EGFR N-Terminal polyclonal, 1:2,000 (ab137660) (Abcam)
and anti-EGFR polyclonal 10005, 1:2,000(sc-03) (Santa Cruz Biotechnology),
all derived from rabbit. Anti-rabbit horseradish peroxidase (Jackson
ImmunoResearch) was used for all blots and images were acquired as above.
Uncropped western blots are shown in Supplementary Fig. 14.
Tracking of EGFR complexes on CHO cells. EGFR expression was induced with
50 ngml 1 doxycycline and if needed, on the following day, cells were transfected
with 1mg of PLCd1-PH-eGFP pCDNA plasmid (gift from Prof Banafshe Larijani,
Universidad del Pais Vasco) using Fugene HD (Roche) as a carrier. Expression was
allowed to proceed for 24 h. Before imaging, cells were starved for 2 h at 37 C in 0.1%
serum supplemented with 50ngml 1 doxycycline. Cells were rinsed twice with 0.1%
serum without doxycycline pre-heated at 37 C. Labelling with Afﬁbody-Alexa 488
was carried out for 10min at 37 C. Cells were rinsed twice with low serum medium
without doxycycline pre-heated at 37 C and promptly imaged as described in
Supplementary Fig. 10.
Mean squared displacement calculations. From single-particle tracks, MSD
curves were calculated as MSD(DT)¼o|ri(TþDT) ri(T)|24, where
|ri(TþDT) ri(T)| is the displacement between position of track i at time T and
time TþDT and the average value is overall pairs of points separated by DT in each
track. The average instantaneous diffusion coefﬁcient (D) for these tracks was
calculated by ﬁtting a straight line to the ﬁrst two points of the MSD curve then
calculating D directly from the gradientm of the ﬁt, D¼m/4. The errors in the MSD
curve were calculated by repeating the MSD curve calculation 200 times, each time
on a different synthetic data set created by randomly resampling with replacement
the time points within each track, the tracks present within each data set, and the
data sets present (bootstrap resampling63). The error in D, s(D), is calculated from
the s.d. of the D ﬁts obtained from each bootstrap-resampled MSD curve.
Molecular dynamics simulations of the EGFR tetramer. Each monomer in the
EGFR tetramer model contained residues 1–995, including 40 residues that are part
of the C-terminal tail. The simulation systems also included two EGF molecules
bound to the tetrameric extracellular domains of EGFR. At the beginning of the
simulations, the two asymmetric kinase dimers were not in close contact with one
another (Supplementary Fig. 5d). Two separate systems of the EGFR tetramer were
set up and simulated. One system (Simulation 1, Fig. 2c) of 24.3 24.3 21.5 nm3
in dimensions contained total 1,151,739 atoms and was simulated up to 40.6 ms.
A smaller but otherwise largely similar system (19.6 13.6 23.0 nm3 in
dimensions, containing 579,306 atoms) was simulated up to 10.6 ms (Simulation 2,
Supplementary Fig. 5d). The simulation system of the face-to-face EGFR
extracellular dimer built based on HER3 crystal dimer had dimensions of
17.0 17.0 17.0 nm3 and contained 472,072 atoms in total; this simulation was
up to 5.98 ms in length (Simulation 3). Each EGFR monomer in system contained
residues 1–614. To mimic the charge distribution in the cellular membrane64, the
model membrane consisted of 100% 1-palmitoyl-2-oleoylphosphatidylcholine
(POPC) lipids in the extracellular leaﬂet and 70% POPC plus 30% 1-palmitoyl-
2-oleoylphosphatidylserine (POPS) lipids in the intracellular leaﬂet of the bilayer.
The distance between the EGF N-terminus and the membrane (as determined by
the distance from the N-terminus to the plane through the phosphates of the
extracellular lipid layer) was computed in a manner consistent with the FRET
measurements, but the size of the ﬂuorophore was not taken into account.
The simulations were performed on a special-purpose supercomputer, Anton 2
(ref. 65), using the Amber ff99SB-ILDN (ref. 66) force ﬁeld for proteins, the
CHARMM C27 force ﬁeld67 for lipids, and TIP3P (ref. 68) for water. The force
ﬁeld for palmitic acid in the simulations of palmitoylated R647C/V650C mutant
was from Forceﬁeld_PTM (ref. 69). The simulated systems were solvated in water
with 0.15M NaCl, with residue protonation states corresponding to pH 7.
Additional Naþ ions were included to neutralize the net charges of the proteins
( 3 for the extracellular domains of each EGFR,  4 for each EGF ligand) and the
POPS lipids. As an equilibration stage, the protein backbone atoms were ﬁrst
restrained to their initial positions using a harmonic potential with a force constant
of 1 kcal mol 1 Å 2. The force constant was linearly scaled down to zero over at
least 50 ns. Simulations were performed in the constant number (N), pressure (P),
and temperature (T) (NPT) ensemble with T¼ 310K and P¼ 1 bar using a
variant70 of the Nose´–Hoover71 and the Martyna–Tobias–Klein algorithm72.
Water molecules and all bond lengths to hydrogen atoms were constrained using
M-SHAKE73. The simulation time step was 1 fs in the equilibration stage and 2 fs in
production simulations; the r-RESPA integration method was used, with long-
range electrostatics evaluated every three time steps electrostatic forces were
calculated in Simulation 1 using the u-series method, a recently developed Ewald-
like method65, with a 1.37 nm cutoff for the electrostatic pairwise summation; a
0.9 nm cutoff for the van der Waals calculations. The electrostatic forces in
Simulations 2 and 3, which were performed earlier, were calculated using the
earlier developed Gaussian split Ewald method74 with a 1.465 nm for the
electrostatic pairwise summation, and a 1.05 nm cutoff for the van der Waals
calculations. All three simulations used a 64 64 64 mesh for the distant
electrostatic calculations.
Data availability. All relevant data are available from the authors on request
and/or are included with the manuscript (as ﬁgure source data or Supplementary
Information Files).
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